RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6th in Boston at 3:00 p.m. ET and the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13th in New York at 12:30 p.m. ET.
Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
2026 Outlook: automated Agentic AI workflows will rapidly emerge as business imperatives to meet patient…
2026 Outlook: automated Agentic AI workflows will rapidly emerge as business imperatives to meet patient…
OVERLAND PARK, Kan.--(BUSINESS WIRE)--#CMSAlignedNetwork--Netsmart, an industry-leading provider of healthcare technology solutions and services for community-based…
From combination surgeries to advanced skin therapies, The Naderi Center outlines how patients nationwide are…
Potential Schedule III Status Could Improve Legal Clarity for Patients Traveling from Colombia to the…
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…